270P - 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography for Evaluation of Biochemical Recurrence of Prostate Cancer - Our Local Experi...

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Prostate Cancer
Genitourinary Cancers
Imaging, Diagnosis and Staging
Presenter Winnie Lam
Citation Annals of Oncology (2017) 28 (suppl_10): x77-x80. 10.1093/annonc/mdx662
Authors C. Goh1, W.W.C. Lam2, M.L.K. Chua3, J. Tan3
  • 1Department Of Nuclear Medicine And Pet, Singapore General Hospital, Singapore/SG
  • 2Department Of Nuclear Medicine And Pet, Singapore General Hospital, 169854 - Singapore/SG
  • 3Division Of Radiation Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG



Evaluation of biochemical recurrence of prostate cancer using conventional imaging is limited in terms of its sensitivity, particularly in the setting of low prostate specific antigen (PSA) values. 68Ga Prostate-specific Membrane Antigen (PSMA) PET is an emerging modality for imaging of prostate cancer recurrence, and has demonstrated high sensitivity even at PSA levels


Retrospective review was performed of the 68Ga-PSMA-11 PET/CT scans of 57 consecutive patients referred to our institution for biochemical recurrence (median PSA 2.6 ng/ml, range 0.13-69.1) following definitive treatment with radical prostatectomy or radiotherapy.


46 out of 57 (81%) of patients showed at least 1 PSMA-positive lesion suggesting prostate cancer recurrence. The detection rate was significantly better at higher PSA values, 93% (37 out of 40) at > 1 ng/ml, 88% (7 out of 8) at 0.5-1.0 ng/ml and 22% (2 out of 9) at 


Our results are largely in line with published data, with the exception of a relatively low detection rate at PSA values

Clinical trial identification


Legal entity responsible for the study

Department of Nuclear Medicine and PET, Singapore General Hospital




All authors have declared no conflicts of interest.